.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Harvard Business School
AstraZeneca
Covington
Moodys
Merck
Cipla
Farmers Insurance
UBS

Generated: December 16, 2017

DrugPatentWatch Database Preview

FIRMAGON Drug Profile

« Back to Dashboard

Which patents cover Firmagon, and what generic alternatives are available?

Firmagon is a drug marketed by Ferring and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and twenty-four patent family members in thirty-six countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
FerringFIRMAGONdegarelix acetatePOWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► Subscribe► Subscribe
FerringFIRMAGONdegarelix acetatePOWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► Subscribe► Subscribe
FerringFIRMAGONdegarelix acetatePOWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► Subscribe► Subscribe
FerringFIRMAGONdegarelix acetatePOWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► SubscribeYY► Subscribe
FerringFIRMAGONdegarelix acetatePOWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► SubscribeYY► Subscribe
FerringFIRMAGONdegarelix acetatePOWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: FIRMAGON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,214,798 GnRH antagonists being modified in positions 5 and 6► Subscribe
8,841,081Method of treating metastatic stage prostate cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FIRMAGON

Country Document Number Estimated Expiration
Portugal2505204► Subscribe
CroatiaP20150633► Subscribe
China1230442► Subscribe
Canada2286190► Subscribe
Turkey9902956► Subscribe
Netherlands300395► Subscribe
China1259959► Subscribe
Brazil9808523► Subscribe
BrazilPI0908129► Subscribe
European Patent Office2249858► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FIRMAGON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/028United Kingdom► SubscribePRODUCT NAME: DEGARELIX OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT SUCH AS THE ACETATE; REGISTERED: UK EU/1/08/504/001 20090217; UK EU/1/08/504/002 20090217
1003774/01Switzerland► SubscribePRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010
2009005,C1003774Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
C0028France► SubscribePRODUCT NAME: DEGARELIX, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/504/001 DU 20090217; REGISTRATION NO/DATE AT EEC: EU/1/08/504/001 DU 20090217
2Finland► Subscribe
0395Netherlands► Subscribe300395, 20180413, EXPIRES: 20230412
585Luxembourg► SubscribePRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
2009000033Germany► SubscribePRODUCT NAME: DEGARELIX, GGF. IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, WIE DEM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001-002 20090217
2009005Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
2009 00022Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Novartis
Queensland Health
Accenture
Federal Trade Commission
Fish and Richardson
US Department of Justice
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot